Abstract:Alexander Xiao, Christopher Warren, Waheeda Samady, Lucy Bilaver Northwestern University Feinberg School of Medicine, Center for Food Allergy and Asthma Research, Chicago, IL, USA Correspondence: Alexander Xiao Email There is a growing body of evidence that atopic skin disease may be due to disturbed microbial composition on the skin. 1 This dysbiosis has been observed in infants with eczema, with certain bacteria such as the Staphylococcal species playing an important role in the process. 2–4 In recent years, treatments for these conditions by altering the skin microbiome have been attempted with some success. One study found that intervention with topically applied R. mucosa was associated with decreased disease severity and S. aureus burden. 5 However, treatment with emollients, probiotic supplementation or "natural" remedies like tea tree oils have had limited evidence of efficacy. 1 Given this role the microbiome plays in atopic disease, our team has developed a novel, topical ointment primarily consisting of probiotics, honey, turmeric and B12 aimed at restoring a healthy skin microbiome. To examine its efficacy, we have completed the preliminary phases of a clinical trial. Our study was conducted as an Investigational New Drug with the FDA with approval from our Institutional IRB. Inclusion criteria were adults 18 and older with dry scalp and dandruff symptoms as determined by a trained research physician. Patients diagnosed with other scalp diseases such as psoriasis, tinea capitis, and pediculosis capitis, used systemic steroid or oral antibiotics in the past two months or had an allergy to any of the preparation components were excluded. Thirty-five adults (55% female, 40% White, 50% Asian, 5% Black, 5% Multiracial) with dry scalp were recruited and followed for this 2-week study. Participant median age was 26; IQR=8 years, range=20–78. The initial study visit consisted of a scalp exam and scalp photographs by a trained research physician to confirm that each participant had a dry scalp condition. At this time participants completed an intake survey including assessment of the participant demographics as well as the standardized assessments of scalp condition history and current symptoms described below. The scalp exam, photographs and intake survey provided the basis for our initial evaluation of disease and symptom severity through the Investigator Global Assessment (IGA), Total Severity Score (TSS) and Scalpdex. The IGA is a 5-point validated instrument that rates overall disease severity according to the following categories: 0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease. The TSS represents the sum of erythema, scaling, and pruritus severity scores of the scalp disease. A minimum TSS score is 0 (none) and the maximum TSS score is 9 (severe). Scalpdex is a validated 23-item quality-of-life questionnaire that is completed by participants to measure their subjective improvement with treatment. Participants were instructed to liberally apply the topical preparation to their scalp once daily for 14 days, leave in place for at least 7 minutes, and rinse in the shower. Participants returned after 14 days of treatment for an in-person follow up including a physician scalp assessment, end photograph and exit survey. At that point, the IGA, TSS and Scalpdex were again determined. Results from paired t -tests with one-sided p-values found that after 2 weeks of treatment, overall disease severity by IGA decreased from 2.1 at baseline to 1.1 at the end of the trial (t(34 df )=8.15; p<0.001). Additionally, mean TSS scores fell from 3.5 at baseline to 1.8 at the conclusion (t(34 df )= p<0.001). Overall Scalpdex decreased from 46.0 to 39.5 (t(33 df )=3.4; p=0.001, reflecting significant reductions in the subjective quality of life burden associated with the scalp condition ( Table 1 ). Notably, significant decreases were observed for all three TSS subscales (p erythema <0.001; p scaling <0.001; p pruritis <0.001) as well as all three Scalpdex subscales (p symptoms =0.001; p emotion <0.001; p functioning =0.04) ( Tables 1 and 2 ). Additionally, the intervention was well-tolerated, without adverse effects or complaints reported by any study participants. Table 1 IGA, TSS and Scalpdex Scores Before and After Intervention Table 2 Scalpdex Score Subscales Before and After Intervention Overall, our preliminary data found that use of a novel, topical dry scalp product clinically reduced the symptoms and disease severity of dry scalp -Abstract Truncated-

A Timosaponin B-II containing scalp care solution for improvement of scalp hydration, dandruff reduction, and hair loss prevention: A comparative study on healthy volunteers before and after application

Molecular Pathways Involved in Promoting Activity of Timosaponin BII on Hair Growth in C57BL/6 Mice

Targeting inflammation and pro-resolving mediators with Anetholea anisita extract to improve scalp condition

An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults

Novel Topical Treatment for Dandruff & Dry Scalp Through Sustained Balance in Skin Microbiome

Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial

Efficacy of Cistanche Tubulosa and Laminaria Japonica Extracts (MK-R7) Supplement in Preventing Patterned Hair Loss and Promoting Scalp Health

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

The Efficacy and Safety Human Study of Narasoo Healing Shampoo and Hair Tonic for Scalp's Lipids & Moisture and Hair Growth -One Center, one group pre-post comparison Pilot Human study-

Comparison of Safety and Efficacy Between Calcipotriol Plus Betamethasone Dipropionate Gel and Calcipotriol Scalp Solution As Long-Term Treatment for Scalp Psoriasis in Chinese Patients: a National, Multicentre, Prospective, Randomized, Active-Controlled Phase 4 Trial

A Study on the Effect of Eclipta Prostrata Extract and MTS on the Improvement of Scalp Health and Prevention of Hair Loss for Workers in Their 20s and 30s

Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation

Scalp application of the antioxidant piroctone olamine reduces hair shedding in an 8-week randomized, double-blind, placebo-controlled clinical study

Reinforcement of barrier function and scalp homeostasis by Senkyunolide A to fight against dandruff

Hair Growth Promotion by Extracts of Inula Helenium and Caesalpinia Sappan Bark in Patients with Androgenetic Alopecia: A Pre-clinical Study Using Phototrichogram Analysis

Effects of Withania somnifera root extract serum application on hair health in healthy adults: A prospective, double-blind, randomized, parallel, placebo-controlled study

A Topical Scalp Serum Containing Adenosine, MgSO4, Vitamin CG, and Pre- and Probiotic Fractions Reduces Discomfort and Associated Symptoms of Sensitive Scalp

Rosemary and neem: an insight into their combined anti-dandruff and anti-hair loss efficacy

Sulforaphane, L-Menthol, and Dexpanthenol as a Novel Active Cosmetic Ingredient Composition for Relieving Hair Loss Symptoms

Efficacy and Safety of a New Topical Hair Loss-Lotion Containing Oleanolic Acid, Apigenin, Biotinyl Tripeptide-1, Diaminopyrimidine Oxide, Adenosine, Biotin and Ginkgo biloba in Patients with Androgenetic Alopecia and Telogen effluvium: A Six-month Open-Label Prospective Clinical Study

Salvianolic Acid B Reduces Oxidative Stress to Promote Hair-Growth in Mice, Human Hair Follicles and Dermal Papilla Cells